List of Wegovy drug patents

Wegovy is owned by Novo.

Wegovy contains Semaglutide.

Wegovy has a total of 5 drug patents out of which 0 drug patents have expired.

Wegovy was authorised for market use on 04 June, 2021.

Wegovy is available in solution;subcutaneous dosage forms.

Wegovy can be used as method for weight management, method for weight management according to a dose escalation schedule.

Drug patent challenges can be filed against Wegovy from December, 2021.

The generics of Wegovy are possible to be released after 17 February, 2041.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(10 years from now)

US10888605 NOVO GLP-1 compositions and uses thereof
Aug, 2038

(15 years from now)

US11318191 NOVO GLP-1 compositions and uses thereof
Feb, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 5, 2022
New Product (NP) Jun 4, 2024

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic